Goldman Sachs
APGN

Goldman Sachs’s Apexigen, Inc. Common Stock APGN Stock Holding History

Goldman Sachs’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-38,170
Closed -$385K – 6841
2022
Q1 		$385K Buy
+38,170
New +$383K ﹤0.01% 5506

Other funds holding APGN

MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Goldman Sachs's APGN Position: Q2 2022 in Review

Goldman Sachs sold out of Apexigen, Inc. Common Stock (APGN) in Q2 2022, closing a stake of 38,170 shares — an estimated $385K sold.

Goldman Sachs first reported a position in APGN in Q1 2022 and held it in 1 quarter. The position peaked at $385K in Q1 2022. 27 funds tracked by Wall St. Rank hold APGN as of Q2 2022.

  • Goldman Sachs reported no remaining Apexigen, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 38,170 Apexigen, Inc. Common Stock shares in Q2 2022, an estimated $385K.
  • Goldman Sachs first reported a position in Apexigen, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Goldman Sachs's Apexigen, Inc. Common Stock position peaked at $385K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.